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Abstract
Cisplatin causes auditory impairment due to the apoptosis of auditory hair cells. There is no strategy to regulate ototoxicity
by cisplatin thus far. Dansam-Eum (DSE) has been used for treating the central nerve system injury including hearing loss in
Korea. However, disease-related scientific investigation by DSE has not been elucidated. Here, we demonstrated that DSE
and its component rosmarinic acid (RA) were shown to inhibit apoptosis of the primary organ of Corti explants as well as the
auditory cells. Administration of DSE and RA reduced the thresholds of the auditory brainstem response in cisplatin-injected
mice. A molecular docking simulation and a kinetic assay show that RA controls the activity of caspase-1 by interaction with
the active site of caspase-1. Pretreatment of RA inhibited caspase-1 downstream signal pathway, such as the activation of
caspase-3 and 9, release of cytochrome c, translocation of apoptosis-inducing factor, up-regulation of Bax, down-regulation
of Bcl-2, generation of reactive oxygen species, and activation of nuclear factor-kB. Anticancer activity by cisplatin was not
affected by treatment with RA in SNU668, A549, HCT116, and HeLa cells but not B16F10 cells. These findings show that
blocking a critical step by RA in apoptosis may be useful strategy to prevent harmful side effects of ototoxicity in patients
with having to undergo chemotherapy.
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Introduction
Cisplatinisa highlyeffective andwidelyusedanticanceragent[1].
The risk of ototoxic and nephrotoxic side effects commonly hinders
the use of higher doses that could maximize its antineoplastic effects
[2]. Cisplatin has been shown to induce auditory sensory cell
apoptosis [3–5]. Devarajan et al. recently reported cisplatin-induced
apoptosis in an immortalized cochlear cell line [6]. Cisplatin toxicity
also was associated with an increase in caspase-3, caspase-8, and
caspase-9 activity, cytochrome c release, apoptosis-inducing factor
(AIF) translocation, reactive oxygen species (ROS) generation, and
nuclear factor-kB( N F - kB) activation [7,8].
Caspase-1 is a member of the cystein-aspartic acid protease
(caspase) family [9]. Caspase-1 is characterized by its ability to
activate the inactive precursors of interleukin (IL)-1b and IL-18,
cytokines that are involved in inflammation. It contains an N-
terminal caspase recruitment domain (CARD). CARD promotes
proteolytic activation of recruited caspases in apoptosis and
inflammation [10].
Given that hair cells do not regenerate in the mammalian
cochlea, cell loss, e.g., due to noise, hypoxia, or cisplatin, is
irreversible and cumulative [4,11]. Cisplatin primarily damages
the outer hair cells (OHCs) of the organ of Corti, which are the
specific effectors of mammalian cochlear amplification and
frequency determination. Larger doses of cisplatin are associated
with additional damage to auditory neurons, stria vascularis, and
supporting cells near the OHCs [12]. Therefore, selective
inhibition of these pathways may provide a strategy to minimize
cisplatin-induced ototoxicity.
Dansam-Eum (DSE) has been used to treat stagnation in the
upper area of the body in Korean Medicine. In particular, DSE
has been used to cure hearing problems that are collectively
expressed as the ‘deficiency syndrome’. Vessel occlusion and
cochlear blood hypo flow are the major cause of noise-induced
hearing loss and idiopathic sudden sensorineural hearing loss. DSE
activates blood and dissipates blood stasis; it promotes blood flow
and removes static blood in the treatment of blood stasis [13].
Rosmarinic acid (RA), a water-soluble polyphenolic component
isolated from DSE, has been reported to have anti-oxidative [14],
anti-inflammatory [15], and anti-depressive activities [16]. Li et al.
reported that RA was found in the brain following intravenous
administration of Salvia miltiorrhiza [17]. Hence, RA can be
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18815considered as an active compound that improves the health of
auditory regulation organs. The aim of this study is to explore the
effect and mechanism of RA on hearing loss.
Results
RA inhibits apoptosis
To determine the effects of DSE, RA (a component of Salvia
miltiorrhiza Bunge) or tanshinnone IIA (a component of Salvia
miltiorrhiza Bunge) on cell viability, HEI-OC1 cells were exposed to
20 mM cisplatin in combination with an increased concentration of
DSE, RA, or tanshinnone IIA. The effect of DSE, RA, or
tanshinnone IIA was initially assessed on viability of HEI-OC1
cells using 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl- tetrazolium
bromide (MTT) assay. As shown Fig. 1A and B, when the cells
were treated for 48 h with cisplatin, the cell viability decreased
significantly compared with media control. DSE or RA inhibited
cisplatin-induced cell death of HEI-OC1 cells. But tanshinnone
IIA did not inhibit cisplatin-induced cell death (data not shown).
This indicates that RA is an active compound of DSE.
To examine whether DSE or RA protects the primary organ of
Corti explants from cisplatin, the half middle turn of the organ of
Corti from neonatal (P2) Sprague Dawley rats was isolated and
treated with DSE or RA and cisplatin for 30 h. Tetramethylrho-
damine isothiocyanate (TRITC)-conjugated phalloidin, which
binds to F-actin (polymeric fibrous actin), was used to stain hair
cells, Hensen’s cells, and Claudius cells in the cochlear explants
cultures. Media control alone did not induce apparent damage on
stereocilia bundles, of which F-actin was intensely labeled with
TRITC conjugated phalloidin. Three rows of OHCs and a single
row of inner hair cells (IHCs) were clearly observed in the
phalloidin staining of a media control group. Treatment with
Figure 1. DSE or RA inhibits apoptosis. HEI-OC1 cells (1610
5/well) were treated with various concentrations of DSE (0.01, 0.1, and
1 mg/ml) or RA (1, 10, and 100 mM) for 4 h and then stimulated with cisplatin (20 mM) for 48 h. Cell viability was estimated by MTT assay
(A and B). The organ of Corti explants were treated with media, 20 mM cisplatin, 1 mg/ml DSE, 100 mM RA, cisplatin plus 1 mg/ml DSE, and cisplatin
plus 100 mM RA for 30 h. The organ of Corti explants were stained with TRITC conjugated phalloidin, and then observed under fluorescent
microscope (C). C57BL/6 mice (each group, n=9) were given orally administration of DSE (1 g/kg) or intraperitoneal injections of RA (4 mg/kg) before
cisplatin for four consecutive days (4 mg/kg body weight per injection). ABR was examined as described in the methodology (D). Results are
representative of three independent experiments. Data are mean 6 S.D. of three independent experiments performed in duplicate. *P,0.01,
compared with unstimulated cells (determined by independent t-test). **P,0.05 compared with cisplatin alone (determined by ANOVA analysis).
doi:10.1371/journal.pone.0018815.g001
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the disarray of three rows of OHCs and a single row of IHCs.
However, pretreatment with DSE or RA apparently provided
protection against cisplatin-induced stereocilia loss in the primary
organ of Corti explants (Fig. 1C). We examined the effect of DSE
(1 g/kg) or RA (4 mg/kg) on cisplatin-induced hearing loss in 8-
week-old C57BL/6. As shown in Fig. 1D, DSE and RA
significantly reduced the cisplatin-induced elevation of auditory
brainstem response (ABR) thresholds. DSE or RA alone had no
effect on ABR thresholds change (data not shown).
Molecular docking of the RA and caspase-1 interaction
To determine whether RA influences to some protein or which
protein is a proper receptor for the RA, docking simulations were
conducted using candidate proteins. Table S1 summarizes the
preliminary docking score of RA with various proteins. RA is
known as a specific inhibitor of the Src homology 2 domains of the
Src family protein tyrosine kinase. The data for the docking scores
indicated that caspase-1 was the best receptor for RA due to its
high docking score relative to the other proteins. This computa-
tional result was well correlated with experimentally determined
Ki values, in which RA ranked the lowest Ki for the caspase-1
protein. The binding mode and affinity of biological substrates and
inhibitors for caspase-1 were examined to compare these
characteristics with those of RA. The molecular docking results
suggested RA is the best ligand for caspase-1. The docking score of
caspase-1-RA was 25.0160.05, which is comparable to the score
of 16.7760.70 for the caspase-1-WEHD-pNA complex (Table 1).
The higher docking score of RA indicates stronger binding affinity
for caspase-1. The calculated docked structures for the ligands
with caspase-1 suggest that WEHD-pNA and RA settle onto an
identical binding site of caspase-1 (Fig. 2A). As capase-1 has no
deep binding cavity for its ligands on its surface, the ligand-binding
process occurs in the shallow crevice on the terminal surface of the
receptor protein. The characterized loop structure of caspase-1
wrapping up both WEHD-pNA and RA were observed to form a
stable docked complex. In particular, RA showed special inter-
atomic interactions, including hydrophobic, electrostatic, and
hydrogen bonding (Fig. 2B). The dihydroxyphenyl moiety of RA
showed hydrophobic interaction with the His237 residue of
caspase-1. The Gly238 and Ser339 residues of caspase-1 were
good hydrogen bond acceptors, and Arg341 acted as both a
hydrogen bond donor and acceptor for the hydroxyl group of RA.
This ligand-bound conformation and the docking score of the RA
with caspase-1 provide atomic-level of its inhibitory effect.
RA inhibits caspase-1 activation
Next, we performed the in vitro assay based on molecular
docking system. Caspase-1 is activated in a variety of cell death
paradigms, and it can be activated by treatment with cisplatin
[18]. The upstream and downstream mediators of the cell death
pathway involving caspase-1 were investigated. To determine if
DSE or RA inhibits caspase-1 activation induced by cisplatin, cells
were exposed to cisplatin in the presence or absence of various
concentrations DSE or RA. Extracts prepared from HEI-OC1
cells exposed to cisplatin contained strong caspase-1 activity
compared with unstimulated cells. As shown in Fig. 3A, increased
caspase-1 activity was significantly inhibited by treatment with
DSE or RA in HEI-OC1 cells. In inner ear tissue, RA also
inhibited the caspase-1 activation (Fig. 3B).
A caspase-1 kinetic assay was used to evaluate the binding affinity
of RA for the caspase-1 catalytic domain. DSE was not used in the
kinetic assay owing to its brown color. Additionally, cisplatin-treated
cell lysate and recombinant caspase-1 were also used to confirm the
effect of RA in the kinetic assay. As shown in Fig. 3C and 3D,
caspase-1 activity was increased after a treatment with WEHD-pNA
(caspase-1 substrate), but RA or caspase-1 inhibitor inhibited the
binding of WEHD-pNA with the caspase-1 catalytic domain. The
inhibition rate by the caspase-1 inhibitor was higher than that of RA
in the cisplatin-treated cell lysate (Fig. 3C). Interestingly, RA
exhibited a more potent binding affinity than did caspase-1 inhibitor
in recombinant caspase-1 (Fig. 3D).This result agreed with molecular
docking simulation. Caspase-1 plays a key role in inflammatory
responses by cleaving pro-IL-1b and pro-IL-18 into secreted pro-
inflammatory cytokines. To investigate the effect of RA on IL-1b
production, the downstream mediators of the cell death pathway
involving caspase-1, ELISA was performed. As shown in Fig. 3E, RA
also significantly inhibited cisplatin-induced IL-1b production.
RA inhibits expression of apoptotic marker by cisplatin
RA revealed a protective effect on cisplatin-induced ototoxicity.
Anti-apoptotic cell-death induced by RA was evidenced by
morphological changes of the cells (data not shown). RA significantly
inhibited nucleosome-sized DNA fragmentation and LDH produc-
tion increased by cisplatin (Fig. 4A and 4B). To determine whether
the inhibition of apoptosis by RA, the early translocation of
phosphatidylserine from the internal toexternal leaflet, a hallmark of
early apoptosis, was investigated by incubating HEI-OC1 cells with
RA. Cisplatin increased the annexin-V binding. Prior treatment of
HEI-OC1 cells with RA blocked annexin-V binding 24 h after the
cisplatin treatment (Fig. 4C and 4D).
Subsequently, the effect of RA on the apoptosis of various cells
was tested using cisplatin in cochlear explant cultures. The organ of
Corti was isolated from rat cochlea on postnatal day 2 and treated
with RA and cisplatin for 30 h. TRITC-conjugated phalloidin was
used to stain the hair cells, Claudius cells and spiral limbus cells in
the cochlear explant cultures. Terminal deoxynucleotidyl transfer-
ase dUTP nick end labeling (TUNEL) staining (green) was used to
detect apoptosis. The cisplatin treatment destroyed the orderly
arrangements of the three rows of OHCs as well as a single row of
IHCs and induced apoptosis in the hair cells, Claudius cells, and
spiral limbus cells. As shown in Fig. 4E, RA inhibited cisplatin-
induced apoptosis. Fig. 4F presents the percentage of apoptotic cells
in the different type of cells in the explants.
RA blocks caspases activity and mitochondrial apoptotic
pathways
Caspase-3, caspase-8, and caspase-9 activity is known to
increase in cisplatin-induced apoptosis in HEI-OC1 cells [19].
Table 1. Docking scores of the top-2% ranked poses for
complexes between different ligands and the caspase-1
protein.
Ligand ChemScore Comment
WEHD-pNA 16.7760.70 Substrate
YVAD-pNA 22.2260.37 Substrate
YVAD-CHO 19.0560.22 Inhibitor
YVAD-CMK 21.3660.36 Inhibitor
RA 25.0160.05
doi:10.1371/journal.pone.0018815.t001
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cisplatin, cells were exposed to cisplatin in the presence or absence
of various concentrations RA. Extracts prepared from HEI-OC1
cells exposed to cisplatin contained strong caspase-3, caspase-8,
and caspase-9 activity compared to unstimulated cells. As shown in
Fig. 5A, increased caspase activities were significantly inhibited by
treatment with RA. However, RA did not inhibit cisplatin-induced
caspase-8 activation.
The mitochondrial apoptotic cascade requires the release of
intermitochondrial membrane cytochrome c to the cytosol [20].
Cytochrome c released from mitochondria into cytosol was
evaluated by a Western blot analysis. The Western blot analysis
indicated that the cisplatin treatment induced a cytochrome c
release and that this was inhibited by treatment with RA (Fig. 5B).
As shown in Fig. 5A, RA did not completely inhibit the cisplatin-
induced caspase activation. As AIF is known to be involved in
apoptosis through a caspase-independent pathway, the possibility
that RA inhibits cisplatin-induced AIF translocation into the
nucleus was examined. Cisplatin was found to induce mitochon-
drial AIF release and translocation to the nucleus. RA prevents
cisplatin-induced AIF translocation (Fig. 5C). Lee et al. reported
that RA effectively suppressed the up-regulation of Bax and down-
regulation of Bcl-2 in neuronal cells [21]. As shown in Fig. 5D, RA
also regulates the Bax and Bcl-2 expression in cisplatin-induced
HEI-OC1 cells.
The effect of cisplatin on intracellular ROS generation was then
assessed. Cells were treated with cisplatin for 24 h. The level of
intracellular ROS was then monitored using a spectrofluorometer
with a peroxide-sensitive fluorescent probe, 29,7 9-dichlorofluor-
escein diacetate (DCFH-DA). As shown in Fig. 5E, treatment with
cisplatin significantly increased the generation of intracellular
ROS. It was found that RA significantly inhibited intracellular
ROS generation by cisplatin in a dose-dependent manner.
RA blocks activation of NF-kB by cisplatin
As activation of NF-kB is linked to apoptosis, it was assumed
that RA mediates its effects at least partly through suppression of
NF-kB activation. Treatment by RA (100 mM) inhibited the
cisplatin-induced increase of the nuclear NF-kB( Rel A/p65) levels
in HEI-OC1 cells. As a marker of NF-kB activation, the
degradation of IkBa in cell lysates was detected. Activation and
nuclear translocation of NF-kB are dependent on the phosphor-
ylation of IkBa, which is then rapidly degraded. It was also shown
that RA inhibits cisplatin-induced IkBa degradation (Fig. 6A). To
Figure 2. Molecular docking of the RA and caspase-1 interaction. Representative docked poses of the highest binding affinities for the
caspase-1 protein with WEHD-pNA and RA (A). Ligand-receptor interaction diagram for the docked pose of RA upon caspase-1 (B). The figure was
drawn with MOE modeling package.
doi:10.1371/journal.pone.0018815.g002
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PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e18815Figure 3. DSE or RA inhibits caspase-1 activation. HEI-OC1 cells (1610
6/well) were treated with various concentrations of DSE
(1 mg/ml) or RA (1, 10, and 100 mM) for 4 h and then stimulated with cisplatin (20 mM) for 48 h. Caspase-1 activity was determined by a
colorimetric kit using substrates in HEI-OC1 cells (A) and inner ear tissue (B). HEI-OC1 cells (1610
6/well) were stimulated with cisplatin (20 mM) for
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examined the effect of RA in a NF-kB-dependent gene reporter
assay. Plasmid NF-kB-luciferase and pSV40-luciferase reporter
gene constructs were transiently cotransfected into HEI-OC1 cells,
which were stimulated by cisplatin. As shown in Fig. 6B, RA
significantly reduced cisplatin-induced luciferase activity. In order
to confirm whether NF-kB/DNA binding is inhibited by RA,
EMSA were utilized. Treatment of cisplatin increased the DNA
binding activity of NF-kB (Fig. 6C), but RA markedly suppressed
cisplatin-induced NF-kB/DNA binding activity.
Effect of RA on cisplatin-treated tumor cells
Cisplatin is an anticancer agent. Therefore, the influence of RA
on cisplatin-induced anticancer activity was investigated. SNU668
(gastric cancer cell), A549 (non small cell lung cancer cells),
HCT116 (colon cancer cell), HeLa (cervical cancer cell), and
B16F10 (melanoma cell) cells were pretreated with RA and then
stimulated with cisplatin. As a result, cisplatin induced apoptosis of
cancer cells. Anticancer activity by cisplatin was not affected by
treatmentwithRAinSNU668,A549,HCT116,andHeLacellsbut
RA inhibited cisplatin-induced apoptosis in B16F10 cells (Fig. 7).
Discussion
Cancer chemotherapeutic strategies commonly require multiple
agents. However, the use of multiple agents contributes to added
toxicity, which often results in poor treatment. Thus, combination
chemotherapy must be optimized to increase tumor response and,
at the same time, lower the level of toxicity. Natural compounds
isolated from plants are used widely in both healthy and diseased
humans. Natural compound have many benefits, few (if any) side
effects and display low cytotoxicity. This study demonstrated that
RA inhibits cisplatin-induced ototoxicity without an effect on the
anticancer activity of cisplatin. It also demonstrated that caspase-1
was a target molecule of RA.
Caspase proteases constitute a family of proteases that normally
exist as inactive enzymes. These are cystein-dependent, aspartate-
specific proteases that function to mediate apoptotic destruction of
the cell [22,23]. Caspases are activated by extrinsic and intrinsic
apoptotic pathways [24]. Caspase-1 is an apical caspase in
neuronal cell death pathways, mediating Bid cleavage, release of
mitochondrial apoptogenic factor (cytochrome c, Smac/Diablo,
and AIF), and activation of caspase-3 and caspase-9 [25]. Recent
research has shown that ovarian cancer cell death is associated
with the activation of caspase-1, caspase-3, and caspase-9 [26]. In
inflammatory responses, caspase-1 becomes part of a protein
complex, the inflammasome, which has similarities to the
apoptosomes in apoptosis [27]. Ghayur et al. reported that
caspase-1 was essential for the maturation of the pro-inflammatory
cytokines pro-IL-1b and IL-18 in lipopolysaccharide-activated
monocytes, as their mature forms are completely absent from
monocytes derived from caspase-1-deficient mice [28]. Caspase-1
also plays a role in the activation of NF-kB, as supported by the
results of experiments using monocytes derived from caspase-1-
deficient mice [23]. The present study showed for the first time
that RA inhibited cisplatin-induced caspase-1 activation in HEI-
OC1 cells. This suggests that RA inhibits cisplatin-induced
apoptosis via a blockade of the caspase-1 pathway.
RA processed anti-oxidant activity as well as anti-inflammatory
activities in vitro and in vivostudies [29,30]. RA suppressed synivitis in
a murine collagen induced arthritis model [31]. Further, RA has
anticarcinogenic effects in a murine, two-stage skin carcinogenesis
model by inhibiting the inflammatory response and scavenging of
reactive oxygen radicals [14]. RA also protected human hepatoma
cells (HepG2) from aflatoxin B1- and ochratoxinmediated cell
damage [32]. RA was shown to inhibit H2O2-induced cell injury by
its anti-apoptotic and anti-oxidant activity [33]. Recently, RA
protects PC12 cells from amyloid-beta peptide-induced neurotox-
icity [34]. In our study, RA inhibited cisplatin-induced apoptosis in
melanomacellswhereasdidnot affectcisplatin-induced apoptosisin
SNU668, A549, HCT116, and HeLa cells. From this, we
presuppose that the protective effects of RA against cisplatin show
difference according to cancer cell types. However, further study is
necessary to clarify the reaction mechanism between cisplatin and
RA in various cancer cells prior to clinical use in patients.
In this study, we showed that RA provided protection against
cisplatin-induced stereocilia loss in the primary organ of Corti
explants. Thus far, effective research regarding natural compound
is attaining much, but research has scarcely been able to
demonstrate a feasible effect because compound interacts with
certain proteins. In this research, it was found via in silico
simulations that RA combines with caspase-1. The molecular
docking results suggested that RA is the best ligand for the caspase-
1. Caspase-1-RA interaction was also confirmed via a kinetic
assay. This evidence indicates that the interaction between RA
and caspase-1 can explain the diverse pharmacological activities of
RA. These findings may also lead to development of more
efficacious therapeutics for hearing loss.
Insummary,we havedemonstrated that treatment of RAinhibited
cisplatin-induced apoptosis via inhibition of ROS generation,
cytochrome c release, caspase activation, AIF translocation, Bax
up-regulation, Bcl-2 down-regulation, NF-kB activation, and IL-1b
production. In this respect, RA may be attributed to decrease the
ototoxic side effect of cisplatin in human being. Further investigation
is necessary to determine other possible anti-apoptotic mechanisms of
RA and to apply it clinically in ototoxicity environments.
Materials and Methods
Ethics statement
All protocols were approved by the institutional animal care and
use committee of Kyung Hee University (Protocol Number.
KHUASP (SE)-10-036).
Materials
DMEM and fetal bovine serum (FBS) were purchased from
Gibco/BRL (Grand Island, NY, USA). Rosmarinic acid, cisplatin,
DMSO, and MTT were purchased from Sigma Chemical (St.
Louis, MO, USA). Caspase-1, cytochrome c, NF-kB, IkBa, Bax,
Bcl-2, and AIF antibodies were obtained from Santa Cruz
Biotechnology (Santacruz, CA, USA). Caspase assay kit, recombi-
nant caspase-1, anti-IL-1b antibody, biotinylated IL-1b antibody,
48 h. Catalytic activity of caspase-1 from cisplatin-treated cell lysate (200 mg, C) or recombinant caspase-1 (8 units, D) was measured by WEHD-pNA
(caspase-1 substrate), RA (1 and 100 mM), or caspase-1 inhibitor (10 mM) for various times. The color development is monitored at 405 nm (C and D).
Each value was calculated from three independent experiments performed in duplicate. IL-1b concentrations were measured in cell supernatants
using the ELISA (E). Data are mean 6 S.D. of three independent experiments performed in duplicate. *P,0.01, compared with unstimulated cells
(determined by independent t-test). **P,0.05 compared with cisplatin alone (determined by ANOVA analysis). #P,0.05, compared with WEHD-pNA
(determined by ANOVA analysis).
doi:10.1371/journal.pone.0018815.g003
RA Prevents Cisplatin-Induced Ototoxicity
PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e18815Figure 4. RA inhibits expression of apoptotic marker by cisplatin. HEI-OC1 cells (1610
6/well) were treated with various concentrations of RA
(1, 10, and 100 mM) for 2 h and then stimulated with cisplatin (20 mM) for 48 h. Internucleosomal DNA fragmentation was quantitatively determined
by assaying for cytoplasmic mononucleosome- and oligonucleosome-associated histone accumulated in membrane-intact cells at the indicated time
points (A). LDH levels on supernatant were assayed by cytotoxic assay kit (B). Apoptosis was measured by staining with FITC-labeled annexin V,
followed by flow cytometric analysis (C), and the percentage of apoptotic cells in the total cell population is shown (D). The basal turns of the cochlea
were stained with TRITC-conjugated phalloidin (red), TUNEL (green), and examined under fluorescent microscope. Results are representative of three
independent experiments (E). The percentage of apoptotic cells in different type of cells in the explants is shown (F). Data are representative of three
independent experiments. Data are mean 6 S.D. of three independent experiments performed in duplicate. *P,0.01, compared with unstimulated
cells. **P,0.05 compared with cisplatin alone. * and ** represent significance determined by independent t-test.
doi:10.1371/journal.pone.0018815.g004
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(Minneapolis, MN, USA). Cytotoxicity detection kit was purchased
from Promega (Medison, WI, USA).
Preparation of DSE
DSE was prepared by decocting the dried prescription of herbs
with boiling distilled water (50 g/l). The duration of decoction was
about 3 h. The decoction was filtered, lyophilized, and kept at
4uC. The yield of extraction was about 10% (w/w). The DSE
water extract powder was dissolved in sterile water (50 g/l). The
ingredients of 50 g DSE include 40 g of Salvia miltiorrhiza Bunge,
5go fSantalum album, and 5 g of Amomum villosum LOUR. The
plants materials were obtained from Oriental drug store, NOA
(Seoul, Republic of Korea) and identified by H.M. Kim, College of
Figure 5. RA blocks cisplatin-induced caspases activation, cytochrome c release, AIF translocation, and ROS generation. HEI-OC1
cells (1610
6/well) were treated with various concentrations of RA (1, 10, and 100 mM) for 2 h and then stimulated with cisplatin
(20 mM) for 48 h. Caspase-3, caspase-8, and caspase-9 activities were determined by a colorimetric kit using substrates (A). Cytochrome c release (B)
into cytosol, AIF translocation to nucleus (C), and Bax/Bcl-2 (D) were determined by Western blot analysis. HEI-OC1 cells (1610
4/well) were treated
with various concentrations of RA (1, 10, and 100 mM) for 2 h. ROS generation was increased 24 h after cisplatin treatment (E). Results are
representative of three independent experiments. Data are mean 6 S.D. of three independent experiments performed in duplicate. *P,0.01,
compared with unstimulated cells (determined by independent t-test). **P,0.05 compared with cisplatin alone (determined by ANOVA analysis).
doi:10.1371/journal.pone.0018815.g005
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specimens (KH090910) have been deposited at the Herbarium
at the College of Oriental Medicine, Kyung Hee University.
Cell viability
HEI-OC1 cells [35] and cancer cells were seeded in 4-well
plates (1610
5 cells) and exposed to various concentrations with
cisplatin. The cell survival fraction was determined with the MTT
assay. Absorption was measured by spectrometer at 540 nm.
Culture of the organ of Corti explants
Spague Dawley rat was sacrificed on postnatal day 2 (P2) and
the cochlea was carefully dissected out. The stria vascularis and
spiral ligament were dissected away leaving the organ of Corti.
The middle turn of the cochlea was used for further analysis.
Cochlea explants were treated with high glucose (4.5 g/l) DMEM
containing 10% FBS, 20 mM cisplatin and 100 mM RA and
further incubated at 37uCi n5 %C O 2 for 30 h. Specimen was
fixed for 15 min in 2% paraformaldehyde in 0.1 M phosphate
buffer (pH 7.4) at room temperature. Specimen was rinsed in
0.1 M PBS, then incubated in 0.25% Triton X-100 for 2 min and
immersed in TRITC-labeled phalloidin in PBS for 20 min. After
three washes with PBS, specimen was examined under fluores-
cence microscope with appropriate filters for TRITC (excitation:
510–550 nm, emission: 590 nm).
Preparation of inner ear tissue
Mice (n=5) were given an ip injection of 2 mg/kg of the
cisplatin for 8 days. RA was dissolved in water and administered
orally 4 h before the injection of cisplatin. Inner ear was isolated at
the 9 days after administration of water or RA. Isolated tissue was
homogenized for caspase-1 assay.
Measurement of ABR
ABR was measured before and 24 h after the final treatment
with cisplatin. TDT system 3 hardware and software (Tucker-
Davis Technologies, Alachua, FL, USA) were used to obtain
ABRs, with 1000 stimulus repetitions per record. Mice were
anesthetized with a cocktail of ketamine (40 mg/kg) and xylazine
(10 mg/kg) and kept warm with a heating pad during ABR
recordings. A subdermal (active) needle electrode was inserted at
the vertex and ground and reference electrodes were inserted
subdermally in the loose skin beneath the pinnae of opposite ears.
Auditory stimuli were recorded in response to 100 ms clicks and
10 ms tone burst with a rise/fall time of 1 ms at 4, 8, 16 and
32 kHz. The sound intensity was progressively decreased in 10-dB
steps and 5-dB steps (click). The ABR threshold was defined as the
lowest stimulus intensity that produced a replicable waveform
response. Weight loss was daily monitored during the eight days
after all reagent (cisplatin, DSE, and RA) treatments and was
supplied 0.6 ml saline solution (intraperitoneally injection, twice/
day) for the protection of death with dehydration.
Figure 6. RA inhibits cisplatin-induced NF-kB activation. HEI-OC1 cells (1610
6/well) were treated with RA (100 mM) for 2 h and then
stimulated with cisplatin (20 mM). Nuclear and cytoplasm protein were prepared and analyzed for NF-kB by Western blotting as described in the
experimental procedures (A). The NF-kB activity was assayed by luciferase assay (B). For the electrophoretic mobility shift assay, the nuclear extract
incubated with
32P-labeled oligonucleotides corresponding to NF-kB was analyzed (C). Data are mean 6 S.D. of three independent experiments
performed in duplicate. *P,0.01, compared with unstimulated cells. **P,0.05 compared with cisplatin alone. * and ** represent significance
determined by independent t-test.
doi:10.1371/journal.pone.0018815.g006
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IL-1b production was measured from cells according to the
manufacturer’s specification using IL-1b assay kit (R & D system
Inc, Minneapolis, MN, USA).
Molecular docking simulation
Molecular docking simulation has been performed using by
GOLD 4.0.1 from Cambridge Crystallographic Data Centre. The
molecular model for each receptor protein, Src-SH2, caspase-1, NF-
kB (p50 homodimer), NF-kB (p65 homodimer), NF-kB (p50p65
heterodimer), and IkBa was obtained from Protein Data Bank (PDB
id 1HCT, 1RWK, 1NFK, 1RAM, 1LE5, and 1IKN, respectively)
without further modification. Preliminary docking was performed for
the system between RA and each receptor protein using the GOLD
program with fast searching option. Following docking simulation
was performed for different ligand with the caspase-1 protein using by
the GOLD program with a ChemScore function. Global searching
was performed using a Lamarckian genetic algorithm with a
maximum number of 1610
6 energy evaluations and 200 individual
populations. Other parameters were applied with a mutation
frequency of 95, a crossover frequency of 95, and a migration
frequency of 10. Independent LGA jobs were carried out for each
ligand with 300 parallel runs. Binding affinities were calculated from
this 200-pose cluster using a ChemScore Fitness function.
Cell death assessment by DNA fragmentation assays
DNA fragmentation was measured from cells according to the
manufacturer’s specification using DNA fragmentation assay kit
(Cell Death Detection ELISA plus kit; Roche Molecular
Biochemicals, Mannheim, Germany).
Annexin V-FITC assay
Apoptosis was determined from cells according to the
manufacturer’s specification using annexin-V-FITC staining kit
(invitrogen, Eugene, Oregon, USA). The percentage of cells
apoptosis was calculated using the Cellquest software (BD
Biosciences, Franklin Lakes, NJ, USA).
TUNEL staining
Apoptosis was detected by TUNEL technique (In Situ Cell
Death Detection Kit, Roche Applied Science, Germany) accord-
ing to manufacturer’s instructions.
Caspase assay
Caspase activity was measured according to the manufacturer’s
specification using caspase assay kit (R & D system). A recombinant
caspase-1, caspase-3, 8, and 9 enzymes are available for use as a
positive control.
Measurement of intracellular ROS generation
The intracellular ROS level was measured using a fluorescent
dye, DCFH-DA (Eastman Kodak, Rochester, NY). In the
presence of an oxidant, DCFH is converted into the highly
fluorescent DCF. Cells were washed twice with serum-free
medium without phenol red and incubated with 5 mM DCFH-
DA in serum-free medium without phenol for 10 min. After
washing twice with serum-free medium without phenol, the
fluorescent intensity was measured at excitation 485 nm and
emission 538 nm in a spectrofluorometer.
Transient transfection and a luciferase assay
For the transfection, we seeded the HEI-OC1 cells (1610
7)i na
100 mm culture dish. We then used Lipofectamine
TM 2000
(Invitrogen, Carlsbad, CA, USA) to transiently transfect pNF-kB-
LUC and pSV40-LUC reporter gene constructs into HEI-OC1
cells. Forty eight hours after the stimulation, we harvested the cells
and washed them in cold PBS before lysing them in a 500 ml lysis
buffer (Dual-LuciferaseH Reporter Assay System; Promega
Corporation, Madison, WI, USA). To measure the luciferase
activity, we used a luminometer (1420 luminescence counter,
Perkin Elmer) in accordance with the manufacturer’s protocol.
The relative luciferase activity was defined as the ratio of firefly
luciferase activity to renilla luciferase activity.
Statistical analysis
The experiments shown are a summary of the data from at
least-three experiments and are presented as the mean 6 S.D.
Statistical evaluation of the results was performed by independent
t-test and ANOVA with Tukey post hoc test. The results were
considered significant at a value of P,0.05.
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